The latest price target for Achieve Life Sciences (NASDAQ:ACHV) was reported by Rodman & Renshaw on November 14, 2024. The analyst firm set a price target for $12.00 expecting ACHV to rise to within 12 months (a possible 225.20% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Achieve Life Sciences (NASDAQ:ACHV) was provided by Rodman & Renshaw, and Achieve Life Sciences initiated their buy rating.

There is no last upgrade for Achieve Life Sciences

There is no last downgrade for Achieve Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achieve Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achieve Life Sciences was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Achieve Life Sciences (ACHV) rating was a initiated with a price target of $0.00 to $12.00. The current price Achieve Life Sciences (ACHV) is trading at is $3.69, which is within the analyst’s predicted range.